title: Adjuvant interferon: extended follow-up times needed?
authors.forename: Fredrik B
authors.initials: FB
authors.lastname: Thoren
authors.forename: Örjan
authors.initials: Ö
authors.lastname: Strannegård
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality* / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D055502:Secondary Prevention; D012878:Skin Neoplasms / Q000188:drug therapy; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins